Risk of Severe COVID-19 Higher with COPD than Asthma

Dawn O'Shea

April 07, 2021

Research led by a team at the University of Oxford has identified that some, but not all, chronic respiratory diseases are associated with a substantially increased risk of severe COVID-19.

In the population cohort study, records from 1205 general practices in England were linked to y Public Health England's database of SARS-CoV-2 testing and English hospital admissions, intensive care unit (ICU) admissions and deaths for COVID-19.

A total of 8,256,161 people aged ≥20 years were included in the cohort and observed between 24 January 2020 and 30 April 2020.

Some respiratory diseases were associated with an increased risk of COVID-19-related hospitalisation compared with those without these diseases:

Some respiratory diseases were associated with an increased risk of COVID-19-related death compared with those without these diseases:

  • COPD (HR, 1.54; 95% CI, 1.42-1.67).

  • Asthma (HR, 0·99; 95% CI, 0·91-1·07).

  • Severe asthma (HR, 1.08; 95% CI, 0.98-1.19).

  • Bronchiectasis (HR, 1.12; 95% CI, 0.94-1.33).

  • Sarcoidosis (HR, 1.41; 95% CI, 0.99-1.99).

  • Extrinsic allergic alveolitis (HR, 1.56; 95% CI, 0.78-3.13).

  • Idiopathic pulmonary fibrosis (HR, 1.47; 95% CI, 1.12-1.92).

  • Other interstitial lung disease (HR, 2.05; 95% CI, 1.49-2.81).

  • Lung cancer (HR, 1,77; 95% CI, 1.37-2.29).

Admission to ICU was rare, but the HR for people with asthma was 1.08 (95% CI, 0.93-1.25) and severe asthma was 1.30 (95% CI, 1.08-1.58).

In a post-hoc analysis, relative risks of severe COVID-19 in people with respiratory disease were similar before and after shielding was introduced on 23 March 2020.

In another post-hoc analysis, people with two or more prescriptions for inhaled corticosteroids (ICS) in the 150 days before study start were at a slightly higher risk of severe COVID-19 compared with individuals receiving no or one ICS prescription, HR for hospitalisation was 1.13 (95% CI, 1.03-1.23) and HRs for ICU admission and death were 1.63 (95% CI, 1.18-2.24) and 1.15 (95% CI, 1.01-1.31), respectively.

Commenting on the findings, published in  Lancet Respiratory Medicine,  the authors conclude that people with COPD and interstitial lung disease appear to have a modestly increased risk of severe disease, but their risk of death from COVID-19 at the height of the epidemic was mostly far lower than the ordinary risk of death from any cause.

The data further suggest that the risk of severe COVID-19 in people with asthma is relatively small and that the use of inhaled steroids might be associated with a modestly increased risk of severe COVID-19.

Aveyard P, Gao M, Lindson N, Hartmann-Boyce J, Watkinson P, Young D, Coupland CAC, Tan PS, Clift AK, Harrison D, Gould DW, Pavord ID, Hippisley-Cox J. Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study. Lancet Respir Med. 2021 Apr 1 [Epub ahead of print]. doi: 10.1016/S2213-2600(21)00095-3. PMID: 33812494 View full text

This article originally appeared on Univadis, part of the Medscape Professional Network.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: